Abstract
Lung Cancer ManagementVol. 2, No. 6 EditorialEGFR–tyrosine kinase mutation testing methods in non-small-cell lung cancer: new diagnostic guidance is NICEAndrew WallaceAndrew WallaceGenomic Diagnostics Laboratory, Manchester Centre for Genomic Medicine, St Mary’s Hospital, Oxford Road, Manchester, M13 9WL, UK. Search for more papers by this authorEmail the corresponding author at andrew.wallace@cmft.nhs.ukPublished Online:28 Nov 2013https://doi.org/10.2217/lmt.13.53AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleReferences1 The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature489(7417),519–525 (2012).Google Scholar2 Bai H, Wang Z, Wang Y et al. Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. PLoS ONE8(2),e54170 (2013).Crossref, Medline, CAS, Google Scholar3 Miyamae Y, Shimizu K, Hirato J et al. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol. Rep.25(4),921–928 (2011).Medline, CAS, Google Scholar101 NICE. Lung cancer. The diagnosis and treatment of lung cancer (CG121). http://guidance.nice.org.uk/CG121Google Scholar102 NICE. EGFR–TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9) (2013). www.nice.org.uk/dg9Google Scholar103 UKNEQAS for Molecular Genetics. EGFR scheme report 2012–2013 (2013). www.ukneqas-molgen.org.uk/ukneqasGoogle ScholarFiguresReferencesRelatedDetailsCited ByImpact of tumor heterogeneity and tissue sampling for genetic mutation testing: a systematic review and post hoc analysisJournal of Clinical Epidemiology, Vol. 126 Vol. 2, No. 6 Follow us on social media for the latest updates Metrics Downloaded 38 times History Published online 28 November 2013 Published in print December 2013 Information© Future Medicine LtdFinancial & competing interests disclosureA Wallace has acted as a consultant on advisory boards for AstraZeneca, Roche Products and Boehringer Ingelheim. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
